In case the resulting β cell-like cells are capable of glucose-regulated insulin secretion, this transdifferentiation strategy might be applicable to PDAC patients with a long-term history of type 2 diabetes and insulin deficiency. The gene discussed is INS; the disease is type 2 diabetes mellitus.